Latest News - DexCom
Top Corporates Hub
DexCom
Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago
13.08.2026 12:30
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
DexCom (NASDAQ:DXCM) Stands Out as an Affordable Growth Stock
04.08.2026 11:10
DexCom earns a 7/10 fundamental rating, blending strong growth, reasonable valuation, and solid profitability as an affordable growth pick.
DexCom (DXCM) Q2 2026 Earnings Call Transcript
04.08.2026 00:15
Revenue hit $1.31 billion with strong international growth and margin expansion.
DexCom: Still A Cautious Buy Following Earnings
03.08.2026 07:16
Dexcom (DXCM) Q2 earnings beat: G7 adoption, global expansion lift margins and FY26 guidance.
DexCom (DXCM) Stock Sees Fair Value Lift After Analyst Target Increases
02.08.2026 06:10
DexCom’s fair value estimate has shifted from US$85.24 to US$91.64, marking a moderate uplift in the price target range currently referenced for the stock. This move lines up with recent analyst commentary, where many firms are reaffirming or raising targets, while a smaller group trims expectations on valuation concerns and growth assumptions. As you read on, you will see how these price target adjustments fit into the broader DexCom narrative and what to watch to stay aligned with the...
Why DexCom (DXCM) Is Up 16.6% After Raising 2026 Outlook And Expanding Type 2 Access
01.08.2026 14:10
In late July 2026, DexCom reported second-quarter results showing higher sales and earnings than a year earlier and raised its full-year 2026 revenue outlook to US$5.18 billion–US$5.25 billion, implying around 11–13% growth. Beyond the headline numbers, DexCom highlighted progress in expanding access for type 2 diabetes patients not using insulin and advancing next-generation sensors, underlining its push into broader metabolic health monitoring. We’ll now look at how DexCom’s raised 2026...
DXCM Q2 Deep Dive: Expanded Access and Product Updates Drive Growth
01.08.2026 04:19
Medical device company DexCom (NASDAQ:DXCM) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.31 billion. The company expects the full year’s revenue to be around $5.22 billion, close to analysts’ estimates. Its non-GAAP profit of $0.70 per share was 15.1% above analysts’ consensus estimates.
DexCom, Inc. 2026 Q2 - Results - Earnings Call Presentation
31.07.2026 05:32
2026-07-31. The following slide deck was published by DexCom, Inc.
DexCom Inc (DXCM) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...
31.07.2026 05:04
DexCom Inc (DXCM) delivered 13% revenue growth and raised full-year guidance, driven by strong international performance and improved margins.
DexCom (DXCM) Q2 2026 Earnings Call Transcript
31.07.2026 01:32
Revenue hit $1.31 billion with strong international growth and margin expansion.
DexCom (DXCM) Could Be 12% Undervalued Following Its Rebound
29.07.2026 13:10
DexCom (DXCM) has been back on radar after its recent share price move, with the stock closing at $74.85. Investors are weighing that price against the company’s current fundamentals and recent trading performance. See our latest analysis for DexCom. The recent 1 day share price return of 2.02% and 90 day share price return of 30.04% suggest momentum has been building for DexCom, even though the 1 year total shareholder return declined 16.23%. If DexCom’s move has you thinking about other...
Stryker's Q2 Results Likely to Reflect Recovery of Q1 Deferred Orders
27.07.2026 13:01
SYK heads into Q2 with robotic surgery momentum, deferred revenue recovery and strong procedure demand as investors watch for earnings and margin trends.
DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion
27.07.2026 13:00
DXCM's Q2 results may reflect strong G7 15 Day adoption, broader reimbursement, and expanding CGM demand as investors watch for continued double-digit revenue growth.
DexCom (DXCM) Earnings Expected to Grow: Should You Buy?
23.07.2026 14:00
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
21.07.2026 13:40
Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
2 Cash-Heavy Stocks on Our Buy List and 1 We Avoid
21.07.2026 11:02
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
DEXCOM INC (NASDAQ:DXCM) Screens as a Strong Growth Stock with Favorable Technical Setup
11.07.2026 10:10
DEXCOM INC (DXCM) shows strong growth with 27% EPS growth and healthy fundamentals, paired with a promising technical breakout setup near $75.38. A compelling blend of quality and timing for growth investors.
Investors’ Confidence in DexCom (DXCM) Rises as Growth Outlook Reassured
09.07.2026 15:15
Bell Global Equities Fund, managed by Bell Asset Management, released its May investor update. A copy of the letter can be downloaded here. The global equity market continued its rally in May, driven by accelerating AI infrastructure spending and a stronger-than-expected earnings season. The Fund (Platform Class) returned 2.1%, underperforming the MSCI World ex-Australia Index’s 4.5% […]
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
09.07.2026 12:30
SAN DIEGO, July 09, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be
Heald Expands Access to AI-Powered Glucose Intelligence for Over-the-Counter CGM Users
09.07.2026 12:30
Consumers purchasing Dexcom Stelo or Abbott Lingo through Heald now receive complimentary access to AI-powered glucose insightsALPHARETTA, Ga., July 09, 2026 (GLOBE NEWSWIRE) -- Heald, a digital metabolic health platform, today announced that consumers who purchase a Dexcom Stelo or Abbott Lingo continuous glucose monitor (CGM) through Heald will now receive complimentary access to the company's AI-powered Glucose Intelligence. The announcement expands access to personalized glucose insights for